Ultragenyx prices upsized IPO at $21, above the range

By Renaissance Capital,

Shutterstock photo

Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised $121 million by offering 5.8 million shares at $21, above the range of $19 to $20. Ultragenyx Pharmaceutical plans to list on the NASDAQ under the symbol RARE. Ultragenyx Pharmaceutical initially filed confidentially on 10/4/2013. J.P. Morgan and Morgan Stanley acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: RARE

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com